Initial therapy for uncomplicated hypertension: Insights from the alphabetic maze of recent studies

Minerva Medica

Volumn 94, Issue 4, 2003, Pages 215-227

  Stewart, J R ^a   Yeun, J Y ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antihypertensive agents; Hypertension, diagnosis; Hypertension, therapy

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; RENIN; RESERPINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL RESEARCH; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COUGHING; DEPRESSION; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DYSPNEA; EDEMA; FATIGUE; HEADACHE; HEALTH CARE COST; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; PRACTICE GUIDELINE; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SLEEP DISORDER; STROKE; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIURETICS; HUMANS; HYPERTENSION; META-ANALYSIS; PRACTICE GUIDELINES;

EID: 0242443240     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45.
2. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157: 2413-46.
3. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
4. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5.
5. McAlister FA, Campbell NR, Zarnke K, Levine M, Graham ID. The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. Can Med Assoc J 2001;164:517-22.
6. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
7. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
8. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-7.
9. Messerli FH, Grossman E. Beta-blockers and diuretics: to use or not to use. Am J Hypertens 1999; 12(12 Pt 1-2):157S-63.
10. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
11. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354: 1751-6.
12. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
13. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.
14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
15. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
16. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967-75.
17. Doggrell SA. ACE inhibitors versus diuretics: ALLHAT versus ANBP2. Expert Opin Pharmacother 2003;4: 825-8.
18. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54.
19. Neal B, MacMahon S, Chapman N, Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.
20. Wang JG, Staessen JA. Conventional therapy and newer drug classes for cardiovascular protection in hypertension. J Am Soc Nephrol 2002;13 Suppl 3:S208-15.
21. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
22. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991;151:1786-92.
23. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
24. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-9.
25. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64.
26. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.
27. Yeun JY. Initial antihypertensive therapy. What are the current drugs of choice? Postgrad Med 2001;110:39-40,43-4,47-8,passi.47m.
28. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
29. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al. Outcome results of the Fosinopril versus Amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
30. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342: 145-53.
32. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
33. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176-83.
34. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-41.
35. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 2000;160:825-31.
36. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344: 1351-7.
37. Staessen JA, Thijs L, Fagard RH, Birkenhager WH, Arabidze G, Babeanu S et al. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998;32:410-6.
38. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC et al. Rationale and design for the Antihypertensive and lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996;9(4 Pt 1):342-60.
39. The Medical Letter. Drugs for hypertension. Med Lett 2003;1:33-9.
40. Weidmann P, de Courten M, Ferrari P, Bohlen L. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol 1993;22 Suppl 6: S98-105.
41. Weir MR, Moser M. Diuretics and β-blockers: is there a risk for dyslipidemia? Am Heart J 2000;139(1 Pt 1):174-83.
42. Moser M. Diuretics and cardiovascular risk factors. Eur Heart J 1992;13 Suppl G:72-80.